Login

Insider Transactions

What ONCOLYTICS BIOTECH INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.

Insider trades

3 months 12 months
Open-market buys 0 14
Sells 0 0
Total trades 0 14

Shares traded

3 months 12 months
Acquired 0 404,282
Disposed 0 0
Net activity +0 +404,282

See the story behind these numbers

View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.

Open-market buyer Disclosed 10b5-1 Heavy discretionary Sign up free

All transactions

Insider Relation Date Transaction Shares Price Value Shares held
Kelly Jared Chief Executive Officer Mar 12 Open-market buy · P +5,050 $0.96 +$4.85K 114,050
Parsons James T. Director Mar 11 Open-market buy · P +10,000 $1.03 +$10.3K 41,849
Brown Deborah Margaret Director Feb 12 Open-market buy · P +25,000 $0.85 +$21.2K 109,851
Heineman Thomas Charles Chief Medical Officer Feb 12 Open-market buy · P +12,132 $0.83 +$10K 282,818
Andrews Patricia S Director Feb 12 Open-market buy · P +35,400 $0.86 +$30.3K 78,128
Hagerman Allison VP, Product Development Feb 12 Open-market buy · P +10,000 $0.83 +$8.3K 115,059
Kelly Jared Chief Executive Officer Feb 12 Open-market buy · P +29,500 $0.84 +$24.8K 109,000
Look Kirk Chief Financial Officer Feb 12 Open-market buy · P +12,000 $0.84 +$10.1K 287,515
Seizinger Bernd R. Director Feb 12 Open-market buy · P +40,000 $0.85 +$33.9K 566,991
Pisano Wayne Director Feb 12 Open-market buy · P +30,000 $0.84 +$25.3K 492,414
Aromando Andrew Chief Business Officer Feb 11 Open-market buy · P +29,600 $0.86 +$25.4K 55,100
Kelly Jared Chief Executive Officer Feb 11 Open-market buy · P +5,600 $0.84 +$4.68K 79,500
Seizinger Bernd R. Director Feb 11 Open-market buy · P +60,000 $0.83 +$49.6K 526,991
Seizinger Bernd R. Director Jan 16 Open-market buy · P +100,000 $1.04 +$104K 466,991

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support